Thyroid Gland DiseaseAnti-TPONCT04249271
Antithyroidal Antibodies With or Without Subclinical Hypothyroidism During Pregnancy in Infertile Women
An observational study of Thyroid Gland Disease and Pregnancy Complications, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
One prospective observational study was carried out in 2009 aiming at identifying the fluctuations of the thyroid hormones in women with normal thyroid gland and in women with anti-TPO antibodies. Serum samples were collected periodically during and after pregnancy in previously infertile women. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Thyroid Gland Disease, Pregnancy Complications
- What is being tested?
- serum sampling
- How many people
- 96 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Feb 2018to 31 Dec 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Healthy women having become pregnancy after infertility.
Who may be able to join
- previous infertility with known thyroidal function (TSH, anti-TPO)
Who cannot join
- other endocrine pathology, such as Addison, diabetes mellitus
- manifest thyroidal pathology, such as Graves disease
- contraindication against pregnancy
- after repeated miscarriage (3 or more)
- heavy smokers (20 cig per day or more)
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Klinik für Gyn. Endokrinologie und Reproduktionsmedizin der Frauenklinik des Universitätsspitals
Basel, 4031
About this study
Official title: Antithyroidale Antikörper Mit Oder Ohne Subklinische Hypothyreose Bei Weiblicher Infertilität in Der Schwangerschaft Und im Wochenbett.
One prospective observational study was carried out in 2009 aiming at identifying the fluctuations of the thyroid hormones in women with normal thyroid gland and in women with anti-TPO antibodies. Serum samples were collected periodically during and after pregnancy in previously infertile women. The samples were stored frozen at -80 °C. Now, the hormone measurements will be carried out.
Read the detailed description
Exclusion of thyroid disease has long been an integral part of a comprehensive infertility work-up, because thyroid function disorders are also associated with disturbances in the menstrual cycle and can cause complications during pregnancy. Subclinical hypothyroidism is the most frequent disease of the thyroid in women of reproductive age (affecting 5 to 10 %). For a long time, measurement of TSH concentration was the only screening parameter used to exclude thyroid disorders. Not only has the differentiation of normal thyroid function (euthyroidism) from the pathological range been controversial for some years but, recently, the role of an elevated anti-TPO antibody titre has also been identified as a significant and independent risk factor for miscarriages and for complications during late pregnancy, even in otherwise euthyroid women. This discovery implies that solely determining the TSH concentration is insufficient. The mechanism underlying the increased rate of complications during pregnancy is also unclear.
The investigators therefore performed a double study to clarify the relative importance of the various possible parameters of thyroid function in the context of an infertility work-up:
- Prevalence study: Measurement of TSH and anti-TPO concentrations in 175 women who present with infertility at the Infertility Clinic at the Women's Hospital, University Hospital Basel. In addition, each participant underwent an ultrasound scan of the thyroid. Control group: 175 healthy women of reproductive age and with regular menstrual cycles, but not currently wishing to have children (recruited via posters in the university and Blood Donor Centre). This study has been finished in 2010. The data of the prevalence study were used to carry out the prospective sampling of the serum samples.
- Prospective measurement of fluctuations in thyroid function during pregnancy and post-partum in a group of euthyroid women and/or those with subclinical hypothyroidism (TSH > 4.5 mIU/l) with/without anti-TPO antibodies. Two different euthyroid groups were defined for the study: Euthyroidism I = TSH 0.3-2.5 mIU/l; Euthyroidism II = TSH 2.5-4.5 mIU/l. Six groups, each with 16 women, divided according to TSH concentration and anti-TPO antibody status, will be required (total 96). All female participants with subclinical hypothyroidism (TSH concentration > 4.5 mIU/l, normal values of peripheral thyroid hormones) receive a T4 supplementation dose. Serum samples will be collected each week from the start of pregnancy up to the 12th week and stored frozen at -80 °C. Thereafter, a serum sample will be collected once a month (up to the 38th week) and stored frozen at -80 °C. Finally, one serum sample post-partum (4 to 6 weeks after delivery) and freeze it. A total of 96 women (16 in each group) were recruited to participate in this study.
After conclusion of the observation period, levels of the following hormones will be measured in the total of 1120 serum samples: TSH, total and free l-thyroxine and fT4 index, total and free triiodothyronine, thyroid autoantibodies (TPO antibodies), hCG, 17β-oestradiol, progesterone, prolactin.
- Conditions
- Thyroid Gland Disease, Pregnancy Complications
- Being tested
- serum sampling
- Keywords
- thyroid, antibody, pregnancy, infertility
- Medical subject headings
- Thyroid Diseases, Pregnancy Complications, Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum samplingOther
repeated serum sampling during pregnancy and thereafter
| Study group | Role | What they receive |
|---|---|---|
| euthyroid, no antibodies | TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling Receives: Other: serum sampling | |
| borderline euthyroid, no antibodies | TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling Receives: Other: serum sampling | |
| hypothyroidism, no antibodies | TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling Receives: Other: serum sampling | |
| euthyroid, with antibodies | TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling Receives: Other: serum sampling | |
| borderline euthyroid, with antibodies | TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling Receives: Other: serum sampling | |
| hypothyroidism, with antibodiesal | TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling Receives: Other: serum sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Deviations from euthyroid function as given by serum levels of TSH (expressed in mIU/l) during pregnancy and after birth.
Impact of antibodies on thyroid function during pregnancy.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2020
- Study start1 Feb 2018
- Primary completion31 Dec 2019
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid Gland DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian De Geyter, University Hospital, Basel, Switzerland
- Investigators
- Christian De Geyter, Prof., Principal investigator, University of Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04249271
- Sponsor's protocol ID
- EKNZ 39-009 00960
- Acronym
- Anti-TPO
- Status last verified
- Jan 2020
- First submitted
- 17 Feb 2018
- Last updated
- 30 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The serum samples are coded and cannot be traced back to individual patients.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antithyroidale Antikörper Mit Oder Ohne Subklinische Hypothyreose Bei Weiblicher Infertilität in Der Schwangerschaft Und im Wochenbett.
- ClinicalTrials.gov ID
- NCT04249271
- Acronym / sponsor ID
- Anti-TPO / EKNZ 39-009 00960
- Conditions
- Thyroid Gland Disease, Pregnancy Complications
- Keywords
- thyroid, antibody, pregnancy, infertility
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 96 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Feb 2018 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 30 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
One prospective observational study was carried out in 2009 aiming at identifying the fluctuations of the thyroid hormones in women with normal thyroid gland and in women with anti-TPO antibodies. Serum samples were collected periodically during and after pregnancy in previously infertile women. The samples were stored frozen at -80 °C. Now, the hormone measurements will be carried out.
Detailed description
Exclusion of thyroid disease has long been an integral part of a comprehensive infertility work-up, because thyroid function disorders are also associated with disturbances in the menstrual cycle and can cause complications during pregnancy. Subclinical hypothyroidism is the most frequent disease of the thyroid in women of reproductive age (affecting 5 to 10 %). For a long time, measurement of TSH concentration was the only screening parameter used to exclude thyroid disorders. Not only has the differentiation of normal thyroid function (euthyroidism) from the pathological range been controversial for some years but, recently, the role of an elevated anti-TPO antibody titre has also been identified as a significant and independent risk factor for miscarriages and for complications during late pregnancy, even in otherwise euthyroid women. This discovery implies that solely determining the TSH concentration is insufficient. The mechanism underlying the increased rate of complications during pregnancy is also unclear.
The investigators therefore performed a double study to clarify the relative importance of the various possible parameters of thyroid function in the context of an infertility work-up:
- Prevalence study: Measurement of TSH and anti-TPO concentrations in 175 women who present with infertility at the Infertility Clinic at the Women's Hospital, University Hospital Basel. In addition, each participant underwent an ultrasound scan of the thyroid. Control group: 175 healthy women of reproductive age and with regular menstrual cycles, but not currently wishing to have children (recruited via posters in the university and Blood Donor Centre). This study has been finished in 2010. The data of the prevalence study were used to carry out the prospective sampling of the serum samples.
- Prospective measurement of fluctuations in thyroid function during pregnancy and post-partum in a group of euthyroid women and/or those with subclinical hypothyroidism (TSH > 4.5 mIU/l) with/without anti-TPO antibodies. Two different euthyroid groups were defined for the study: Euthyroidism I = TSH 0.3-2.5 mIU/l; Euthyroidism II = TSH 2.5-4.5 mIU/l. Six groups, each with 16 women, divided according to TSH concentration and anti-TPO antibody status, will be required (total 96). All female participants with subclinical hypothyroidism (TSH concentration > 4.5 mIU/l, normal values of peripheral thyroid hormones) receive a T4 supplementation dose. Serum samples will be collected each week from the start of pregnancy up to the 12th week and stored frozen at -80 °C. Thereafter, a serum sample will be collected once a month (up to the 38th week) and stored frozen at -80 °C. Finally, one serum sample post-partum (4 to 6 weeks after delivery) and freeze it. A total of 96 women (16 in each group) were recruited to participate in this study.
After conclusion of the observation period, levels of the following hormones will be measured in the total of 1120 serum samples: TSH, total and free l-thyroxine and fT4 index, total and free triiodothyronine, thyroid autoantibodies (TPO antibodies), hCG, 17β-oestradiol, progesterone, prolactin.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| euthyroid, no antibodies | – | Other: serum samplingTSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling |
| borderline euthyroid, no antibodies | – | Other: serum samplingTSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling |
| hypothyroidism, no antibodies | – | Other: serum samplingTSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling |
| euthyroid, with antibodies | – | Other: serum samplingTSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling |
| borderline euthyroid, with antibodies | – | Other: serum samplingTSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling |
| hypothyroidism, with antibodiesal | – | Other: serum samplingTSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy women having become pregnancy after infertility.
Key inclusion criteria (1 listed)
- previous infertility with known thyroidal function (TSH, anti-TPO)
Key exclusion criteria (5 listed)
- other endocrine pathology, such as Addison, diabetes mellitus
- manifest thyroidal pathology, such as Graves disease
- contraindication against pregnancy
- after repeated miscarriage (3 or more)
- heavy smokers (20 cig per day or more)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum samplingrepeated serum sampling during pregnancy and thereafter | Other | borderline euthyroid, no antibodies, borderline euthyroid, with antibodies, euthyroid, no antibodies, euthyroid, with antibodies, hypothyroidism, no antibodies, hypothyroidism, with antibodiesal |
Primary outcome
Deviations from euthyroid function as given by serum levels of TSH (expressed in mIU/l) during pregnancy and after birth.
Time frame: 12 months
Impact of antibodies on thyroid function during pregnancy.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jan 2020.
- Individual participant dataSharing planned: No. The serum samples are coded and cannot be traced back to individual patients.
Related trials for Thyroid Gland Disease
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian De Geyter, Prof. principal investigator
University of Basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Gland Disease and Pregnancy Complications, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Deviations from euthyroid function as given by serum levels of TSH (expressed in mIU/l) during pregnancy and after birth. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2020.